Free Trial

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

-0.04 (-5.20%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
49.09 million shs
Average Volume
31.53 million shs
Market Capitalization
$1.57 billion
P/E Ratio
Dividend Yield
Price Target

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
1.67 Rating Score
151.6% Upside
$1.90 Price Target
Short Interest
20.84% of Float Sold Short
Dividend Strength
News Sentiment
0.24mentions of Ginkgo Bioworks in the last 14 days
Based on 29 Articles This Week
Insider Trading
Insiders Both Buying and Selling
Proj. Earnings Growth
From ($0.30) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

698th out of 921 stocks

Biological Products, Except Diagnostic Industry

110th out of 152 stocks

DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

Is Ginkgo Bioworks Holdings Stock a Buy?
Analysts Set Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) PT at $2.20
Ginkgo Bioworks: Massive Revenue Warning
Ginkgo Bioworks (NYSE:DNA) Shares Gap Down to $0.92
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$251.46 million
Book Value
$0.55 per share


Outstanding Shares
Free Float
Market Cap
$1.60 billion
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" DNA shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

6 brokerages have issued 12-month price objectives for Ginkgo Bioworks' stock. Their DNA share price targets range from $1.00 to $3.00. On average, they predict the company's stock price to reach $1.90 in the next twelve months. This suggests a possible upside of 151.6% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2024?

Ginkgo Bioworks' stock was trading at $1.69 on January 1st, 2024. Since then, DNA stock has decreased by 55.3% and is now trading at $0.7551.
View the best growth stocks for 2024 here

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 289,730,000 shares, an increase of 8.7% from the April 15th total of 266,530,000 shares. Based on an average daily trading volume, of 30,860,000 shares, the short-interest ratio is currently 9.4 days. Approximately 20.8% of the company's shares are sold short.
View Ginkgo Bioworks' Short Interest

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our DNA earnings forecast

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its earnings results on Thursday, May, 9th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $37.94 million for the quarter, compared to the consensus estimate of $45.50 million. Ginkgo Bioworks had a negative net margin of 409.11% and a negative trailing twelve-month return on equity of 56.09%. During the same quarter in the previous year, the business earned ($0.08) EPS.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170.0 million-$190.0 million, compared to the consensus revenue estimate of $223.2 million.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (10.83%), Vanguard Group Inc. (5.85%), Sumitomo Mitsui Trust Holdings Inc. (2.60%), Nikko Asset Management Americas Inc. (2.60%), Salem Investment Counselors Inc. (0.22%) and Nordea Investment Management AB (0.20%). Insiders that own company stock include Barry Canton, Christian O Henry, Harry Sloan, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 5/21/2024 by Staff

From Our Partners